Atlas Trials

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Clinical trial NCT01377922 · COMPLETED

Trial details

NCT number
NCT01377922
Sponsor
Catalyst Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Lambert Eaton Myasthenic Syndrome
Start date
2011-06-01
Primary completion
2016-07-01
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.